Mursla Bio joins ABHI US Accelerator to launch EvoLiver in the US market
Mursla Bio has been selected for the ABHI US Accelerator, supporting the US launch of EvoLiver, its FDA-designated liver cancer surveillance test, by providing access to healthcare leaders and operational guidance.
Mursla Bio announced it has been selected to join the Association of British HealthTech Industries (ABHI) US Accelerator. Building on the Company’s US presence, the program will support the introduction of EvoLiver, its FDA-designated liver cancer surveillance test, to the US market.
The ABHI program will provide Mursla Bio with structured access to more than 300 senior healthcare leaders across 35 leading hospitals, 20 health systems, and US insurers. It also offers direct operational guidance from Becton Dickinson, Dell Medical School at the University of Texas, and ABHI’s US advisor network. This access is expected to accelerate EvoLiver’s path into clinical workflows, helping convert launch readiness into early adoption across specialist hepatology centers.
EvoLiver is a blood test designed to improve liver cancer detection in high risk patients by leveraging hepatocyte-specific EV biology, addressing key limitations of standard approaches.
